Bristol-Myers Bristol-Myers Squibb Co announced that ®, a PD-1 inhibitor, has been approved by China's State Drug Administration to add two new indications for esophageal cancer: neoadjuvant radiotherapy and chemotherapy (CRT) and adjuvant therapy for esophageal cancer or gastroesophageal junction cancer with pathological residue after complete surgical resection. Combined with fluorouracil and platinum-containing chemotherapy is suitable for first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma.